Aisling Capital IV, LP - 29 Jun 2021 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role: 10%+ Owner
Signature: AISLING CAPITAL IV, LP, by Aisling Capital Partners IV, LP, its General Partner, by Aisling Capital Partners IV LLC, its General Partner, /s/ Andrew Schiff, Managing Member
Issuer symbol: ELEV
Transactions as of: 29 Jun 2021
Net transactions value: +$3,000,000
Form type: 4
Filing time: 01 Jul 2021, 18:29:04 UTC
Previous filing: 24 Jun 2021
Next filing: 22 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELEV	Common Stock	Conversion of derivative security	$0	+1,893,232	+640%	$0.000000	2,189,050	29 Jun 2021	Direct	F1, F2
transaction	ELEV	Common Stock	Conversion of derivative security	$0	+458,360	+21%	$0.000000	2,647,410	29 Jun 2021	Direct	F1, F2
transaction	ELEV	Common Stock	Purchase	$3,000,000	+187,500	+7.1%	$16.00^*	2,834,910	29 Jun 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELEV	Series A Preferred Stock	Conversion of derivative security	$0	-8,000,000	-100%	$0.000000^*	0	29 Jun 2021	Common Stock	1,893,232		Direct	F1, F2
transaction	ELEV	Series B Preferred Stock	Conversion of derivative security	$0	-1,936,834	-100%	$0.000000^*	0	29 Jun 2021	Common Stock	458,360		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date.
F2	The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

Content

The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date.

The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.